All News

Under pressure from Congress and public scrutiny, Pfizer voluntarily pulled its controversial television campaign for Lipitor featuring Dr. Jarvik.

A new study shows that while doctors aren't in a rush to stop prescribing Vytorin, they are considering it less often as a first-line treatment option.

Pfizer's consumer ads for Lipitor are causing a stir on the blogs and in Congress. Did the company cross the line by using a famous (but unlicensed) doctor to market a drug, or is this a case of a mistaken identity?

More and more consumers are surfing the Web for information about prescription drugs, but many bypass brand.com sites, a new report says.

Healthcare Education Services has announced details of two additional oncology specific courses to add to its comprehensive range of medical education for the pharmaceutical industry.

Lilly is in the midst of settlement discussions with federal prosecutors over the pharma company?s off-label marketing of the antipsychotic medication Zyprexa. If settled, Lilly could be shelling out more than $1 billion in fines.

Merck is under investigation for allegedly pushing physicians to prescribe Vioxx for unapproved use. Federal investigators are scrutinizing Merck?s marketing and sales practices in search of shady business tactics.

Global marketing strategies and the business opportunities in Japan

Congress blocked DTC user fees, Reagan-Udall, field force reforms while slightly bumping FDA's budget

After watching similar legislation barring data mining for Rx info get shut down in Maine and New Hampshire, Vermont changes tactics and amends its law.

In the wake of the ENHANCE study, new prescriptions of the cholesterol-lowering drug Vytorin are dropping drastically, but calls to sales reps by physicians are on the rise.

Unlike Vioxx, Vytorin works exactly as explained in its now-famous food-and-family ads. So why are people up in arms against the drug? Experts ponder what went wrong.

In a surprising but not completely unexpected move, FDA announced last week that its Prescription Drug User Fee Act was dead on arrival. Feds cite lack of funding as main reason.

Managed care pharmacy executives list their favorite pharmaceutical companies based on promotional activities and the ability to meet managed care needs. Novartis reigns for 11th straight quarter.

New report finds that neither sales reps nor patient requests are the deciding factor when it comes to physician prescribing habits, information is-the more the better.

New study finds that risks and side effects don't get their fair share of time in television advertising. The authors cry out for more educational information in DTC ads--but is it necessary if the ads aren't breaking the law?

Pricing, safety, comparative effectiveness, patents, and biosimilars top 2008's policy agenda

Pharma defends itself against claims made in charity's report on drug access for the world's poor

A new report says FDA is desperately behind on science. At last, a critique we can actually do something about. But will we?

Economist Conference, Pharma 2020

When it comes to clinical teams, the question of whether or not to outsource brings some untraditional answers

Pharma companies would do well to proceed with extreme caution when entering the blogosphere

GlaxoSmithKline locks up MediaCom as its only ad-buying/planning provider. The agency will handle GSK's massive ad spend, which last year hovered around $1.1 billion.

Drug manufacturer shakes things up with new Web site that functions as an open book into the world of Vertex Pharmaceuticals. The company hopes that its transparent approach to design will be a lesson to pharma companies still fearful of online media.

European Sales Manager

The European CRO industry is becoming more competitive and complex by the day. What will it take to remain successful in this rapidly evolving landscape? Alan Morgan investigates.

Science is the lifeblood of pharma, of course. But these days, science isn't just what you produce in your own labs. It's what you can license, buy, partner on, or gain through acquisition. Which means that, increasingly, deals are the lifeblood of pharma.